Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. Our lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals.

Nexavar is approved in more than 70 countries worldwide for the treatment of patients with advanced kidney cancer, and in more than 40 countries for the treatment of patients with liver cancer.

As a part of a broad development program, Nexavar is currently being evaluated in randomized trials in non-small cell lung cancer, breast cancer, melanoma and other cancers. The agent is also being studied in multiple Phase 2 trials, as well as in several Phase 1b studies evaluating its use in combination with standard chemotherapies and other anticancer agents. In addition, we have a small molecule cell cycle inhibitor resulting from a collaboration with Pfizer that entered clinical testing in 2004.

By exploiting the genetic differences between cancer cells and normal cells, Onyx is focused on providing a new generation of improved cancer therapeutics.

Since our establishment in 1992, we have been guided by the vision of founder Frank McCormick, Ph.D., F.R.S., an internationally recognized scientist and currently Director of the University of California San Francisco Comprehensive Cancer Center and Cancer Research Institute. This vision, which is demonstrated by our slogan Changing the way cancer is treated™, has led to the discovery of proprietary compounds that target cancer cells while minimizing damage to normal cells.

Onyx common stock is traded on the Nasdaq Global Market under the symbol ONXX.